Announcements Trials
Browse Landscape

Phase

Phase 2 73Phase 3 47Phase 1 27Phase 1/2 18Phase 2/3 4Phase NA 2Phase 4 1

Status

Recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Radiotherapy 10Nivolumab 10Bevacizumab 10atezolizumab 8Radiation 8Platinum 8Pemetrexed 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Surgical Procedures, Operative 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Cytarabine 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Oxaliplatin × 90 days × Clear all
NCT05139017 2026-06-04

waveLINE-003

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
290 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07462143 2026-05-22

A Phase â…¡/â…¢ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

RemeGen Co., Ltd.

Phase 2/3 Recruiting
80 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06280495 2026-04-20

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Sun Yat-sen University

Phase 2/3 Recruiting
156 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07490262 2026-04-16

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Phase 2/3 Recruiting
680 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡